Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by mediascan59on Jun 10, 2010 11:31am
674 Views
Post# 17176879

Wading through the garbage

Wading through the garbageFirst of all, the recent post on TA is total BS. If you wanted to look at the TA right now, Full Sto has bottomed and is creeping up if ever so slowly. MACD has been rising over the past few days and is getting very close to crossing over to the positive...Monday or Tuesday from the  looks of it. RSI is sitting at such a bottom that there is tons of room, not only there but from all the indicators to absorb an incredible rise in the price of the stock...spells gap up to me if it happens.
But...as I stated before, TA is not useful at this particular period of time, as the direction all depends upon the release regarding the placebo effect.
Too many issues against that type of testing for an accurate comparison, so what we can only look at until the release is that our drug did work and it has a history of workiing. That puts the odds in SSS favvour that the release will be positive and the stock will get back on track.
At that point, then we can look to the TA for guidance once again.
There must be a few that agree with me because since that release, approximately 60 million shares have traded hands at an average price of 10 cents.
Sounds like quite a few are williing to take the gamble.

Happy Trading all,
Mediascan
Bullboard Posts